NIAID Emerging and Re-emerging Infectious Diseases NIAID Bioinformatics Resource Centers NIAID Structural Genomic Centers Center for Structural Genomics of Infectious Disease
Seattle Structural Genomics Center for Infectious Disease

MymaA.00213.a: Enoyl-CoA hydratase, EchA21

Target Characteristics

from organism: Mycobacterium marinum ATCC BAA-535 / M
most recent status: purified
center reference id: MymaA.00213.a
is community request: False
associated disease: Cutaneous ulcerations, deep abscesses
NIH risk group: 2
is select agent: False
NIH priority
pathogens category:
IIIC

Ordering Clones & Proteins

If there are materials available for this target, they will be listed below. Materials can be ordered from SSGCID using the button in the "order material" column. Clicking the button will add the material to a virtual cart. You may order multiple materials at a time at no cost to you, as this contract is funded by NIAID. When you are ready to place your order, click the "Place Order" link which will appear in the top right corner of the page after you place your first item in your cart.

Clones*

CENTER
REFERENCE ID
DOMAIN/REGION
DESCRIPTION
INFO AA
START
AA
STOP
ORDER
MATERIAL
MymaA.00213.a.A1.GE29961 Full length( MymaA.00213.a ) 1 274 GE29961
* SSGCID clones represent un-induced expression constructs which have been verified by sequencing from vector primers. Clones may contain a tag, such as N-term 6xHis. Get sequence information using the button in the "info" column.

Proteins

CENTER
REFERENCE ID
DOMAIN/REGION
DESCRIPTION
INFO AA
START
AA
STOP
ORDER
MATERIAL
MymaA.00213.a.A1.PW29837 Full length( MymaA.00213.a ) 1 274

External Resources

Resource Reference ID
OrthoMCL: OG5_129459
PATRIC ID: fig|216594.6.peg.5713
RefSeq: YP_001853588.1
UniProt: B2HLK1

Enzyme & Pathway Information

Pathway Pathway ID EC Number
fatty acid beta-oxidation I FAO-PWY 4.2.1.17
L-isoleucine degradation I ILEUDEG-PWY 4.2.1.17
oleate beta-oxidation PWY0-1337 4.2.1.17
phenylacetate degradation I (aerobic) PWY0-321 4.2.1.17
benzoyl-CoA degradation I (aerobic) PWY-1361 4.2.1.17
fermentation to 2-methylbutanoate PWY-5109 4.2.1.17
fatty acid beta-oxidation II (peroxisome) PWY-5136 4.2.1.17
unsaturated, even numbered fatty acid beta-oxidation PWY-5138 4.2.1.17
superpathway of glyoxylate cycle and fatty acid degradation PWY-561 4.2.1.17
superpathway of phenylethylamine degradation PWY-6071 4.2.1.17
4-hydroxybenzoate biosynthesis III (plants) PWY-6435 4.2.1.17
fatty acid beta-oxidation VI (peroxisome) PWY66-391 4.2.1.17
pyruvate fermentation to hexanol (engineered) PWY-6863 4.2.1.17
superpathway of cholesterol degradation I (cholesterol oxidase) PWY-6928 4.2.1.17
superpathway of testosterone and androsterone degradation PWY-6937 4.2.1.17
androstenedione degradation PWY-6944 4.2.1.17
superpathway of cholesterol degradation II (cholesterol dehydrogenase) PWY-6947 4.2.1.17
methyl ketone biosynthesis (engineered) PWY-7007 4.2.1.17
4-coumarate degradation (anaerobic) PWY-7046 4.2.1.17
fatty acid salvage PWY-7094 4.2.1.17
jasmonic acid biosynthesis PWY-735 4.2.1.17
docosahexaenoate biosynthesis III (6-desaturase, mammals) PWY-7606 4.2.1.17
(8E,10E)-dodeca-8,10-dienol biosynthesis PWY-7654 4.2.1.17
Spodoptera littoralis pheromone biosynthesis PWY-7656 4.2.1.17
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate biosynthesis (6-desaturase) PWY-7726 4.2.1.17
toluene degradation to benzoyl-CoA (anaerobic) PWY-81 4.2.1.17
L-valine degradation I VALDEG-PWY 4.2.1.17

Sequences

These sequences are the native gene sequence; sequences of constructs derived from these sequences may differ due to codon optimization or other protocols. To find the specific sequence of any material you may have ordered, click on the "more" button next to the name of that material.
AA Sequence
MGETYESVTV EIKDQVAQVT LIGPGKGNAM GPAFWSELPE VFAALDADRD VRAIVITGSG KNFSYGLDVP AMGGTFAPLM AEGALARPRT DFHAEVLRMQ KATNAVADCR TPTIASVHGW CIGGGVDLIS AVDMRYASAD AKFSIREVKL AIVADMGSLA RLPMILNDGH LRELALTGRD IDAARAEKIG LVNQVFEDAD ATLAAAHATA TEIAANPPLA VYGVKDVLDQ QRASAVAENL RYVAAWNAAF LPSKDLTEGI SATFAKRPPQ FTGE

NT Sequence
ATGGGCGAAA CATACGAATC TGTCACCGTC GAGATCAAAG ACCAGGTCGC ACAGGTGACG TTGATCGGGC CGGGCAAGGG TAATGCAATG GGACCCGCTT TCTGGTCGGA GCTGCCGGAA GTCTTCGCGG CGCTGGACGC CGACCGTGAT GTGCGGGCGA TCGTCATCAC CGGGTCGGGC AAGAACTTCA GTTACGGACT GGACGTGCCG GCGATGGGTG GAACTTTCGC CCCGCTGATG GCCGAAGGGG CGCTGGCGCG TCCCCGCACC GACTTTCATG CCGAGGTGCT GCGGATGCAG AAGGCGACCA ATGCGGTCGC CGATTGCCGG ACCCCGACCA TCGCGTCGGT GCACGGCTGG TGCATTGGCG GCGGCGTCGA CCTGATCTCG GCGGTGGACA TGCGCTACGC GAGTGCGGAT GCGAAGTTCT CGATACGCGA GGTCAAGCTC GCCATCGTCG CCGACATGGG CAGCCTGGCC CGCCTTCCGA TGATCCTCAA CGACGGTCAT CTGCGGGAGC TGGCGCTGAC CGGTCGGGAT ATCGACGCCG CTCGGGCCGA GAAGATCGGC CTGGTCAACC AGGTGTTCGA AGACGCCGAC GCAACCTTGG CCGCCGCCCA CGCCACCGCC ACCGAGATTG CCGCCAATCC CCCGCTGGCG GTGTACGGCG TCAAAGACGT CCTCGACCAG CAGCGCGCGT CGGCCGTCGC GGAAAACCTG CGCTACGTCG CGGCCTGGAA TGCGGCGTTT CTGCCGTCCA AGGACCTCAC CGAGGGAATA TCGGCGACCT TCGCCAAGCG GCCTCCCCAG TTCACCGGGG AG

© 2022 Seattle Children's Research Institute. All rights reserved.